Loading…
ENTX
Entera Bio Ltd.
NASDAQ· Healthcare· Biotechnology· CUSIP M40527109
$3.03-1.62%Price as of Aug 29, 18:37 UTC · updated once a day, after the close
Key metrics
- Market cap
- $524.62M
- P/E
- —
- Forward P/E
- —
- P/B
- 20.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.35
- ROE
- -138.92%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.40
- 52-week high
- $4.20
- 52-week low
- $0.91
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -35.6% over 5Y.
today you would have $582.80▼ -41.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.94 | $2.12 | $0.60 | $0.73 | |
| P/S | 454.9x | 2133.0x | 454.9x | — | 156.9x |
| P/B | 4.4x | 6.8x | 10.2x | 2.0x | 1.8x |
| EPS | -$0.25 | -$0.25 | -$0.31 | -$0.45 | |
| Profit margin | -9754.48% | -27235.71% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| EOLSEvolus, Inc. | $8.00 | — | — | — | — | $528.4M |
| ASMBAssembly Biosciences Inc | $25.45 | 20.5x | 1.7x | — | -0.03% | $518.18M |
| KYTXKyverna Therapeutics, Inc. | $8.37 | — | 2.6x | — | -87.24% | $517.63M |
| SENSSenseonics Holdings, Inc. | $10.06 |
About the company
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
- 20
- Jerusalem, Israel
Company description provided by Yahoo Finance.